Contact

Get Help Now

WI IL IA

Before You Choose NuvaRing, Read This

Young women are busy. Many are balancing both families and jobs. Their unpredictable schedules can make it hard to use low-dose oral contraceptives, which must be taken at the same time each day. For these women, NuvaRing is a convenient alternative.

The NuvaRing is easy to use. The flexible vaginal ring is left in the body for three weeks where it releases a steady stream of the hormones estrogen and progestin. On the fourth week, the ring is taken out. It is replaced at the end of that week.

The estrogen in NuvaRing comes from etonogestrel, a derivative of the drug desogestrel. Oral contraceptives containing desogestrel and its derivatives have been linked to an increased risk of blood clots. But doctors believed that the low dose in the NuvaRing would make the vaginal ring safer that a traditional birth control pill.

Although the NuvaRing contraceptive has been marketed as a safe and convenient alternative to traditional birth control pills, several studies have shown that women who use NuvaRing may actually have a greater risk of blood clots than women who use contraceptive pills.

NuvaRing and Blood Clot Risk

  • In 2011, the U.S. Food and Drug Administration released a research report documenting as much as a 56 percent increase in blood clot risk among NuvaRing users.
     
  • A Danish study published in the British Medical Journal on May 10, 2012, found up to a 90 percent increased risk of blood clots in women using NuvaRing compared to women using traditional oral contraceptives.
     
  • In June 2014, a study in The New England Journal of Medicine linked the use of NuvaRing to as much as a 300 percent increase in blood clot risk.
     

While these blood clots are very painful, they can also be life-threatening. The clots can break loose and travel to the brain causing a stroke, or to the lungs causing a pulmonary embolism. Women who survive these complications are often left with permanent disabilities, including brain injury and paralysis.

As of 2013, the FDA had received more 5,000 reports of NuvaRing injuries. More than 3,800 women have filed lawsuits against Merck, the maker of the drug.

If you have suffered a blood clot, DVE, DVT, stroke, or pulmonary embolism while using NuvaRing, please contact Hupy and Abraham. You may be eligible to take part in a NuvaRing lawsuit. To learn more, please call 800-800-5678.

Jason F. Abraham
Managing Partner, Hupy and Abraham
Be the first to comment!
Post a Comment